

# SenesTech Ramps up Manufacturing to Meet Demand

FLAGSTAFF, Ariz., Jan. 25, 2017 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES), a developer of proprietary technologies for managing animal pest populations through fertility control, announced today that it is ramping up manufacturing capabilities to meet demand in 2017 and beyond for the company's innovative new rodent control technology, ContraPest. The Company's existing manufacturing capacity, estimated at 300,000 liters per year, is expected to double under the current expansion plans.

A key component of the unique manufacturing line for ContraPest is custom microencapsulating. SenesTech has secured order of the equipment necessary for that, and expects the new manufacturing line can be deployed within three to four months.

"Our Flagstaff manufacturing line was planned and built to meet early launch capacity, however, the increasing demand from customers for ContraPest indicates a need for additional manufacturing capacity," said Dr. Loretta P. Mayer, Chair, CEO and co-founder of SenesTech. "Our equipment suppliers have expressed their continued support for our efforts, and have pledged to provide priority access and preferential pricing on many components. Having already successfully deployed commercial-scale production capabilities, we are confident our experienced product production team is poised to bring the additional capacity online in a rapid and efficient manner."

## About SenesTech

SenesTech has developed an innovative technology for managing animal pest populations through fertility control as opposed to a lethal approach.

The Company's first fertility control product, ContraPest<sup>®</sup>, will be marketed for use initially in controlling rat infestations. ContraPest's novel technology and approach targets the reproductive capabilities of both sexes, inducing egg loss in female rodents and impairing sperm development in males. Using proprietary bait stations, ContraPest is dispensed in a highly palatable liquid formulation that promotes sustained consumption by rodent communities. ContraPest is designed, formulated and dispensed to be safe for handlers and non-target species such as wildlife, livestock and pets, in a biodegradable product. In contrast, the historical approach to managing rodent pest populations, rodenticides, carries a high risk of environmental contamination and the poisoning of non-target animals, pets and children.

We believe our non-lethal approach, targeting reproduction, is more humane, less harmful to the environment, and more effective in providing a sustainable solution to pest infestations than traditional lethal pest management methods. There is currently no other non-lethal fertility control product approved by the Food and Drug Administration (FDA), or the Environmental Protection Agency (EPA), for the management of rodent populations. We believe ContraPest<sup>®</sup> will establish a new paradigm in rodent control, resulting in improved performance in rodent control over rodenticides, without the negative environmental effects of rodenticides. For more information visit the SenesTech website at [www.senestech.com](http://www.senestech.com).

## Safe Harbor Statement

*This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors and other risks identified in our filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such*

*date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.*

SOURCE SenesTech, Inc.

For further information: Investor: Robert Blum, Joe Dorame, Joe Diaz, Lytham Partners, LLC, 602-889-9700, [senestech@lythampartners.com](mailto:senestech@lythampartners.com); Company: Tom Chesterman, Chief Financial Officer, SenesTech, Inc, 928-779-4143

---

<https://senestech.investorroom.com/2017-01-25-SenesTech-Ramps-up-Manufacturing-to-Meet-Demand>